EBOS Group Limited Logo

EBOS Group Limited

EBO.NZ

(2.8)
Stock Price

37,00 NZD

5.22% ROA

10.73% ROE

28.35x PER

Market Cap.

6.905.556.000,00 NZD

72.75% DER

3.06% Yield

2.03% NPM

EBOS Group Limited Stock Analysis

EBOS Group Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

EBOS Group Limited Fundamental Stock Analysis
# Analysis Rating
1 Assets Growth

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

2 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

3 ROE

The stock's ROE falls within an average range (11.16%), demonstrating satisfactory profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (5.22%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

5 PBV

The stock's PBV ratio (2.72x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

6 DER

The stock has a reasonable amount of debt compared to its ownership (73%), suggesting a balanced financial position and a moderate level of risk.

7 Revenue Growth

Company's revenue has experienced consistent growth over the last three years, indicating a favorable financial trajectory and making it an attractive investment choice.

8 Net Profit Growth

Throughout the last three years, this company has experienced consistent net profit growth, reflecting a robust financial performance and making it an attractive investment prospect.

9 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (2.183) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

10 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

11 Dividend Growth

The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.

EBOS Group Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

EBOS Group Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

EBOS Group Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

EBOS Group Limited Revenue
Year Revenue Growth
1995 27.997.637
1996 0 0%
1997 57.143.446 100%
1998 0 0%
1999 0 0%
2000 0 0%
2001 105.808.713 100%
2002 206.418.000 48.74%
2003 224.017.000 7.86%
2004 227.657.117 1.6%
2005 280.256.000 18.77%
2006 300.300.000 6.67%
2007 306.998.000 2.18%
2008 1.089.169.000 71.81%
2009 1.340.927.000 18.77%
2010 1.370.899.000 2.19%
2011 1.340.977.000 -2.23%
2012 1.426.515.000 6%
2013 1.821.971.000 21.7%
2014 5.757.234.000 68.35%
2015 6.068.080.000 5.12%
2016 7.101.455.000 14.55%
2017 7.625.854.000 6.88%
2018 7.609.488.000 -0.22%
2019 7.250.847.458 -4.95%
2020 9.381.932.998 22.71%
2021 9.888.133.663 5.12%
2022 11.901.673.134 16.92%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

EBOS Group Limited Research and Development Expenses
Year Research and Development Expenses Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

EBOS Group Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 1.568.081 100%
2002 2.156.971 27.3%
2003 2.140.144 -0.79%
2004 2.093.602 -2.22%
2005 2.376.225 11.89%
2006 28.112.000 91.55%
2007 28.847.000 2.55%
2008 58.724.000 50.88%
2009 66.791.000 12.08%
2010 65.696.000 -1.67%
2011 56.328.000 -16.63%
2012 68.125.000 17.32%
2013 88.367.000 22.91%
2014 231.936.000 61.9%
2015 237.264.000 2.25%
2016 263.947.000 10.11%
2017 295.591.000 10.71%
2018 357.370.000 17.29%
2019 357.611.425 0.07%
2020 347.691.320 -2.85%
2021 382.433.652 9.08%
2022 467.055.106 18.12%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

EBOS Group Limited EBITDA
Year EBITDA Growth
1995 3.571.348
1996 5.179.540 31.05%
1997 4.367.813 -18.58%
1998 4.742.540 7.9%
1999 7.012.957 32.37%
2000 6.371.000 -10.08%
2001 9.965.334 36.07%
2002 206.418.000 95.17%
2003 11.205.000 -1742.2%
2004 15.648.333 28.39%
2005 19.579.000 20.08%
2006 22.445.000 12.77%
2007 19.152.000 -17.19%
2008 34.615.000 44.67%
2009 38.959.000 11.15%
2010 46.205.000 15.68%
2011 41.489.000 -11.37%
2012 49.046.000 15.41%
2013 60.314.000 18.68%
2014 183.700.000 67.17%
2015 202.565.000 9.31%
2016 234.644.000 13.67%
2017 244.893.000 4.19%
2018 278.199.000 11.97%
2019 266.694.915 -4.31%
2020 354.607.728 24.79%
2021 391.567.637 9.44%
2022 456.265.661 14.18%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

EBOS Group Limited Gross Profit
Year Gross Profit Growth
1995 27.997.637
1996 0 0%
1997 57.143.446 100%
1998 0 0%
1999 0 0%
2000 0 0%
2001 105.808.713 100%
2002 206.418.000 48.74%
2003 224.017.000 7.86%
2004 227.657.117 1.6%
2005 280.256.000 18.77%
2006 67.844.000 -313.09%
2007 71.570.000 5.21%
2008 126.678.000 43.5%
2009 145.861.000 13.15%
2010 151.475.000 3.71%
2011 134.220.000 -12.86%
2012 163.281.000 17.8%
2013 224.496.000 27.27%
2014 570.083.000 60.62%
2015 603.635.000 5.56%
2016 682.932.000 11.61%
2017 753.664.000 9.39%
2018 860.644.000 12.43%
2019 846.264.909 -1.7%
2020 987.111.206 14.27%
2021 1.066.337.166 7.43%
2022 1.380.712.939 22.77%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

EBOS Group Limited Net Profit
Year Net Profit Growth
1995 2.233.093
1996 3.481.413 35.86%
1997 2.982.023 -16.75%
1998 2.764.877 -7.85%
1999 4.251.000 34.96%
2000 188.000 -2161.17%
2001 96.000 -95.83%
2002 -379.000 125.33%
2003 -110.000 -244.55%
2004 0 0%
2005 -731.000 100%
2006 11.548.000 106.33%
2007 10.319.000 -11.91%
2008 16.663.000 38.07%
2009 19.727.000 15.53%
2010 23.437.000 15.83%
2011 31.579.000 25.78%
2012 27.949.000 -12.99%
2013 28.207.000 0.91%
2014 92.069.000 69.36%
2015 105.941.000 13.09%
2016 126.997.000 16.58%
2017 132.846.000 4.4%
2018 149.564.000 11.18%
2019 144.067.797 -3.82%
2020 173.946.270 17.18%
2021 199.094.230 12.63%
2022 224.642.422 11.37%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

EBOS Group Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 1 0%
2012 0 0%
2013 1 0%
2014 1 0%
2015 1 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 1 100%
2021 1 0%
2022 1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

EBOS Group Limited Free Cashflow
Year Free Cashflow Growth
1995 2.230.594
1996 3.770.355 40.84%
1997 -904.876 516.67%
1998 -1.514.514 40.25%
1999 -1.206.398 -25.54%
2001 5.683.770 121.23%
2002 7.993.578 28.9%
2003 -6.832.827 216.99%
2004 5.585.564 222.33%
2005 5.582.036 -0.06%
2006 6.860.000 18.63%
2007 4.831.000 -42%
2008 22.081.000 78.12%
2009 31.443.000 29.77%
2010 39.157.000 19.7%
2011 17.816.000 -119.79%
2012 24.252.000 26.54%
2013 22.552.000 -7.54%
2014 78.845.000 71.4%
2015 118.348.000 33.38%
2016 212.997.000 44.44%
2017 106.349.000 -100.28%
2018 -63.344.000 267.89%
2019 -35.782.591 -77.02%
2020 -31.340.041 -14.18%
2021 -88.385.086 64.54%
2022 -99.383.524 11.07%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

EBOS Group Limited Operating Cashflow
Year Operating Cashflow Growth
1995 2.504.303
1996 4.059.874 38.32%
1997 10.178 -39788.72%
1998 0 0%
1999 0 0%
2001 6.666.588 100%
2002 10.098.350 33.98%
2003 0 0%
2004 8.658.386 100%
2005 6.532.036 -32.55%
2006 8.349.000 21.76%
2007 7.254.000 -15.1%
2008 28.546.000 74.59%
2009 33.310.000 14.3%
2010 41.813.000 20.34%
2011 21.703.000 -92.66%
2012 28.112.000 22.8%
2013 26.415.000 -6.42%
2014 114.152.000 76.86%
2015 133.789.000 14.68%
2016 224.122.000 40.31%
2017 143.943.000 -55.7%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

EBOS Group Limited Capital Expenditure
Year Capital Expenditure Growth
1995 273.709
1996 289.519 5.46%
1997 915.054 68.36%
1998 1.514.514 39.58%
1999 1.206.398 -25.54%
2001 982.818 -22.75%
2002 2.104.772 53.31%
2003 6.832.827 69.2%
2004 3.072.822 -122.36%
2005 950.000 -223.45%
2006 1.489.000 36.2%
2007 2.423.000 38.55%
2008 6.465.000 62.52%
2009 1.867.000 -246.28%
2010 2.656.000 29.71%
2011 3.887.000 31.67%
2012 3.860.000 -0.7%
2013 3.863.000 0.08%
2014 35.307.000 89.06%
2015 15.441.000 -128.66%
2016 11.125.000 -38.8%
2017 37.594.000 70.41%
2018 63.344.000 40.65%
2019 35.782.591 -77.02%
2020 31.340.041 -14.18%
2021 88.385.086 64.54%
2022 99.383.524 11.07%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

EBOS Group Limited Equity
Year Equity Growth
1995 5.621.746
1996 7.672.048 26.72%
1997 9.460.748 18.91%
1998 10.600.525 10.75%
1999 12.404.401 14.54%
2000 35.475.000 65.03%
2001 38.861.897 8.72%
2002 45.986.946 15.49%
2003 44.562.427 -3.2%
2004 48.177.116 7.5%
2005 50.426.634 4.46%
2006 55.763.000 9.57%
2007 94.150.000 40.77%
2008 147.304.000 36.08%
2009 162.039.000 9.09%
2010 182.790.000 11.35%
2011 198.796.000 8.05%
2012 208.601.000 4.7%
2013 304.877.000 31.58%
2014 979.039.000 68.86%
2015 1.051.028.000 6.85%
2016 1.087.277.000 3.33%
2017 1.132.070.000 3.96%
2018 1.192.959.000 5.1%
2019 1.299.781.335 8.22%
2020 1.407.414.107 7.65%
2021 1.516.088.965 7.17%
2022 2.511.156.447 39.63%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

EBOS Group Limited Assets
Year Assets Growth
1995 12.601.873
1996 13.863.891 9.1%
1997 26.054.648 46.79%
1998 29.512.934 11.72%
1999 35.180.184 16.11%
2000 0 0%
2001 60.353.580 100%
2002 90.388.259 33.23%
2003 92.620.297 2.41%
2004 92.539.010 -0.09%
2005 119.114.305 22.31%
2006 134.735.000 11.59%
2007 137.226.000 1.82%
2008 486.194.000 71.78%
2009 499.833.000 2.73%
2010 518.343.000 3.57%
2011 538.319.000 3.71%
2012 657.999.000 18.19%
2013 2.531.739.000 74.01%
2014 2.309.293.000 -9.63%
2015 2.550.058.000 9.44%
2016 3.192.896.000 20.13%
2017 3.205.574.000 0.4%
2018 3.263.298.000 1.77%
2019 3.350.295.041 2.6%
2020 4.010.264.369 16.46%
2021 4.243.857.312 5.5%
2022 6.945.941.900 38.9%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

EBOS Group Limited Liabilities
Year Liabilities Growth
1995 6.980.127
1996 6.191.843 -12.73%
1997 16.593.900 62.69%
1998 18.912.409 12.26%
1999 22.775.783 16.96%
2000 0 0%
2001 21.491.683 100%
2002 44.401.313 51.6%
2003 48.057.870 7.61%
2004 44.203.116 -8.72%
2005 64.683.671 31.66%
2006 78.972.000 18.09%
2007 43.076.000 -83.33%
2008 338.890.000 87.29%
2009 337.794.000 -0.32%
2010 335.553.000 -0.67%
2011 339.523.000 1.17%
2012 449.398.000 24.45%
2013 2.226.862.000 79.82%
2014 1.330.254.000 -67.4%
2015 1.499.030.000 11.26%
2016 2.105.619.000 28.81%
2017 2.053.176.000 -2.55%
2018 2.047.080.000 -0.3%
2019 2.053.726.721 0.32%
2020 2.607.209.676 21.23%
2021 2.733.485.549 4.62%
2022 4.560.360.350 40.06%

EBOS Group Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
67.27
Net Income per Share
1.27
Price to Earning Ratio
28.35x
Price To Sales Ratio
0.58x
POCF Ratio
0
PFCF Ratio
-69.48
Price to Book Ratio
2.54
EV to Sales
0.69
EV Over EBITDA
17.88
EV to Operating CashFlow
0
EV to FreeCashFlow
-82.09
Earnings Yield
0.04
FreeCashFlow Yield
-0.01
Market Cap
6,91 Bil.
Enterprise Value
8,16 Bil.
Graham Number
20.14
Graham NetNet
-12.56

Income Statement Metrics

Net Income per Share
1.27
Income Quality
0
ROE
0.11
Return On Assets
0.04
Return On Capital Employed
0.11
Net Income per EBT
0.69
EBT Per Ebit
0.8
Ebit per Revenue
0.04
Effective Tax Rate
0.29

Margins

Sales, General, & Administrative to Revenue
0.04
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.12
Operating Profit Margin
0.04
Pretax Profit Margin
0.03
Net Profit Margin
0.02

Dividends

Dividend Yield
0.03
Dividend Yield %
3.06
Payout Ratio
0.76
Dividend Per Share
1.1

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
-0.56
Capex to Operating CashFlow
0
Capex to Revenue
-0.01
Capex to Depreciation
0
Return on Invested Capital
0.05
Return on Tangible Assets
0.05
Days Sales Outstanding
46.75
Days Payables Outstanding
67.99
Days of Inventory on Hand
43.08
Receivables Turnover
7.81
Payables Turnover
5.37
Inventory Turnover
8.47
Capex per Share
-0.56

Balance Sheet

Cash per Share
3,24
Book Value per Share
14,19
Tangible Book Value per Share
-1.44
Shareholders Equity per Share
14.19
Interest Debt per Share
10.47
Debt to Equity
0.73
Debt to Assets
0.26
Net Debt to EBITDA
2.75
Current Ratio
1.22
Tangible Asset Value
-0,25 Bil.
Net Current Asset Value
-1,16 Bil.
Invested Capital
0.73
Working Capital
0,61 Bil.
Intangibles to Total Assets
0.38
Average Receivables
1,38 Bil.
Average Payables
1,77 Bil.
Average Inventory
1042537976.58
Debt to Market Cap
0.26

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

EBOS Group Limited Dividends
Year Dividends Growth
2009 0
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 1 0%
2017 1 0%
2018 1 0%
2019 1 0%
2020 1 0%
2021 1 0%
2022 1 0%
2023 1 0%

EBOS Group Limited Profile

About EBOS Group Limited

EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, New Zealand, and internationally. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and multi-brand retail pharmacy services. It also offers vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; community based health care services and programs; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that helps members drive their retail businesses. In addition, the company supplies health and wellness products to public and private hospitals, day surgeries, general practice, aged care facilities, specialist clinics, government, and non-profit health agencies, as well as clinically essential products; and provides pharmacy services to private and public hospitals, cancer centers, correctional facilities, and veterinary clinics. Further, it offers contract logistics services, such as healthcare distribution, warehousing, clinical trial management, and product registration services; clinical trial logistics; aesthetic healthcare devices, medical-grade cosmeceuticals, and injectables; and surgical devices and medical consumables. Additionally, the company provides pet nutrition and food products, treats, clean-up products, grooming, and accessories; and wholesales veterinary products for companion animals, production animals, and equine athletes. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was incorporated in 1922 and is headquartered in Docklands, Australia.

CEO
Mr. John Cullity
Employee
5.000
Address
737 Bourke Street
Docklands, 3008

EBOS Group Limited Executives & BODs

EBOS Group Limited Executives & BODs
# Name Age
1 Mr. Simon Bunde
Executive General Manager of Strategic Operations, ESG & Innovation
70
2 Ms. Janelle Cain
General Counsel
70
3 Mithran Naiker
Chief Information Officer
70
4 Ms. Jacinta McCarthy
Group General Manager of Human Resources
70
5 Mr. John Cullity
Chief Executive Officer
70
6 Mr. Leonard Hansen
Chief Financial Officer & Chief Accountant
70
7 Ms. Julie Dillon
Chief Executive Officer of Animal Care
70
8 Mr. Matthew Muscio
Chief Executive Officer of Medical Technology
70
9 Mr. Brett Barons
Chief Executive Officer of Symbion
70

EBOS Group Limited Competitors